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A B S T R A C T
The nervous system, in addition to be a target for steroid hormones, is the source of a variety of neuroactive
steroids, which are synthesized and metabolized by neurons and glial cells. Recent evidence indicates that the
expression of neurosteroidogenic proteins and enzymes and the levels of neuroactive steroids are different in the
nervous system of males and females. We here summarized the state of the art of neuroactive steroids, parti-
cularly taking in consideration sex differences occurring in the synthesis and levels of these molecules. In ad-
dition, we discuss the consequences of sex differences in neurosteroidogenesis for the function of the nervous
system under healthy and pathological conditions and the implications of neuroactive steroids and neuroster-
oidogenesis for the development of sex-specific therapeutic interventions.
1. Introduction
Steroidogenesis (Fig. 1) is particularly prominent in the peripheral
glands that synthesize hormonal steroids, such as the adrenals and the
gonads. However, it is a more generalized phenomenon than the
synthesis of steroid hormones and is not restricted to the steroidogenic
glands. Thus, cells in many tissues metabolize cholesterol to produce
steroids for local actions. For instance, in the nervous system, neurons
and glial cells synthesize steroids that regulate neural function by au-
tocrine and paracrine mechanisms. These local steroid actions are ex-
erted in parallel, but with independence, of the endocrine signaling by
steroid hormones. Baulieu and his collaborators were the first to iden-
tify steroidogenic activity in the nervous system and termed “neuro-
steroids” the steroids produced by neural cells (Corpechot et al., 1981).
Steroidogenic activity is now well-documented in fish, reptiles,
birds and mammals (Cascio et al., 2015; Diotel et al., 2018; Garcia-
Segura and Melcangi, 2006; Melcangi et al., 2008; Panzica and
Melcangi, 2008; Pelletier, 2010; Porcu et al., 2016; Spanic et al., 2015;
Weger et al., 2018). Consequently, significant levels of steroids are
detected in the nervous system and these levels do not necessarily re-
flect those in plasma and cerebrospinal fluid (CSF) (Caruso et al.,
2013b; Kancheva et al., 2011; Kancheva et al., 2010; Melcangi et al.,
2011). However, the identification of a given steroid in the brain, the
spinal cord or the peripheral nerves does not provide direct information
on its site of synthesis. Indeed, both neurosteroids and steroid hormones
contribute to determine the steroid levels in neural tissue. Therefore, in
this paper we use the more general term “neuroactive steroids”, which
currently refers to steroids that have an activity in the nervous system,
with preference to the name neurosteroids.
The accumulated information on the synthesis, metabolism, levels
and actions of neuroactive steroids in the nervous system in recent
years calls for a critical analysis of the implication of these molecules
for brain function under physiological and pathological conditions.
Thus, in the next sections, we will review sex differences in the levels of
neuroactive steroids and in the expression of steroidogenic molecules in
CNS and PNS under both physiological and pathological conditions. We
will also discuss the available information on the physiopathological
consequences of such sex differences in neuroactive steroid levels and
neurosteroidogenesis for CNS physiology and for the manifestation of
neurodegenerative and psychiatric disorders. In this regard, the op-
portunity offered by neuroactive steroids and neurosteroidogenesis for
the development of neuroprotective interventions will be examined.
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Finally, we will discuss neuroinflammation as a possible functional
target for sex-specific therapies based on neuroactive steroids.
2. Influence of sex and gonadal hormones on
neurosteroidogenesis under physiological conditions
2.1. Sex differences in neurosteroidogenesis
An important aspect of neurosteroidogenesis is that it is a sexually
differentiated process. For instance, brain progesterone (PROG) levels
and its metabolites are higher in pseudopregnant female rats than in
males (Meffre et al., 2007) and neuroactive steroid levels in different
brain regions show basal sex differences (Caruso et al., 2013b) (Fig. 2).
Sex differences in neuroactive steroid levels are probably due in part
to differences in neurosteroidogenic machinery. For instance, sex dif-
ferences are observed in the frog brain, where steroidogenic acute
regulatory protein (StAR) gene expression increases during the re-
productive phase in male but not in female brain (Santillo et al., 2017).
In the brain of catfish Heteropneustes fossilis, the levels of 3beta-hydro-
xysteroid dehydrogenase (3β-HSD) show sex differences depending on
the seasonal phase and brain regions considered (Mishra and Chaube,
2017). 3β-HSD expression is higher in brain slices from juvenile zebra
finch females than in the corresponding brain slices from males (Tam
and Schlinger, 2007). In green anole lizards, there is a higher gene
expression of an isoform of 5alpha-reductase (5α-R) (i.e., the type 2) in
the brain of females than in males (Cohen and Wade, 2010). In the quail
brain, aromatase also shows sex differences, with higher enzymatic
activity in males than in females (Balthazart et al., 2011).
Similarly, in rodents, aromatase gene expression and protein levels
are higher in male amygdala neuronal cultures (Cisternas et al., 2017)
as well as in vivo (Cisternas et al., 2015). Further observations indicate a
higher aromatase expression in the bed nucleus of the stria terminalis
and medial amygdaloid nucleus of male animals (Stanic et al., 2014).
Sex differences in other steroidogenic molecules have been also
detected in the rodent brain. For instance, StAR gene expression in the
adult rat cerebellum is significantly higher in proestrus females (i.e.,
data in other phases of the estrous cycle are not available) than in males
(Giatti et al., 2019; Lavaque et al., 2006a; Lavaque et al., 2006b). The
basal mRNA levels of 3alpha-hydroxysteroid oxidoreductase (3α-
HSOR) are also significantly higher in females, at the proestrus day,
than in males. On the contrary, the mRNA levels of translocator protein
of 18 kDa (TSPO) and 5α-R are significantly higher in males. In the
cerebral cortex, the mRNA expression of StAR, TSPO, P450 side chain
cleavage (P450scc), 3β-HSD, 5α-R and 3α-HSOR is similar in males and
females (Giatti et al., 2019). It is interesting to note that not only the
neurosteroidogenic machinery shows sex differences, but also the
homeostasis of cholesterol, the substrate of steroidogenesis, is different
in male and female rats in brain regions such as the hippocampus and
prefrontal cortex (Segatto et al., 2013).
2.2. Influence of sex steroid hormones on neurosteroidogenesis
One of the possible causes of sex differences in the levels of neu-
roactive steroids and in the expression of steroidogenic molecules in the
nervous system is the different gonadal hormone environment in males
and females. Indeed, several studies have shown that the nervous
system adapts the local levels of neuroactive steroids to the physiolo-
gical changes in steroid hormones coming from sex peripheral glands.
Thus, there is a relationship between gonadal hormones and the ner-
vous levels of neuroactive steroids. Indeed, our previous observations
have indicated that gonadectomy affects the levels of neuroactive
steroids in the CNS and the PNS (Caruso et al., 2010b). Interestingly,
the changes in neuroactive steroid levels in the nervous system after
gonadectomy present regional specificity between the different CNS
Fig. 1. Steroidogenic pathways. Formation of PREG from free cholesterol, occurring in the mitochondria, represents the first step of steroidogenesis. Translocation of
free cholesterol into mitochondria is regulated by a molecular complex composed by several proteins (i.e., TSPO, StAR and the voltage-dependent anion channel
protein, VDAC). Formation of PREG occurs by the action of the enzyme P450scc. This neuroactive steroid is then converted in the endoplasmic reticulum into PROG
by the enzyme 3β-HSD or into DHEA by the enzyme cytochrome P450c17. DHEA is the substrate for the synthesis of androgens, such as T. This neuroactive steroid is
metabolized into 17β-E by the action of the enzyme aromatase or into DHT by the action of the enzyme 5α-R, which also converts PROG into DHP. DHT and DHP are
then further converted by the enzymes 3α- or 3β-HSOR, into 3α-diol or 5α-androstane-3β,17β-diol (3β-diol) in case of DHT, and into THP or isopregnanolone in case
of DHP. Abbreviations in the text. The arrows and bidirectional arrows indicate the irreversible and reversible reactions respectively.
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areas and between the CNS and the PNS and do not necessarily reflect
the changes in plasma steroid levels. Moreover, the effects of gona-
dectomy are different in males and females and depend on the duration
of gonadal hormone deprivation (i.e., short or long-term castration)
(Caruso et al., 2010b).
Recent results indicate that, at least in some cases, the sex specific
effects of long-term gonadectomy are associated with alterations in the
expression of the neurosteroidogenic machinery. For instance, in female
rats the expression of 3β-HSD in the cerebral cortex and the expression
of 3α-HSOR in the cerebellum are decreased after long-term ovar-
iectomy, while the expression of P450scc and TSPO in the cerebral
cortex and the expression of StAR in the cerebellum are increased by
the same experimental procedure (Giatti et al., 2019). In contrast, long-
term orchidectomy induces an increase in the expression of TSPO and a
decrease in the expression of 5α-R in male cerebellum (Giatti et al.,
2019).
In this context, it is also important to highlight that other factors,
such as ligands of TSPO (Da Pozzo et al., 2016; Wolf et al., 2015) or
PPAR-α (Locci and Pinna, 2019), vitamin D (Emanuelsson et al., 2018),
D-aspartate (Di Fiore et al., 2018) and vasotocin (Nagarajan et al.,
2015) are able to stimulate neurosteroidogenesis. In addition, maternal
fructose consumption during gestation and lactation affects neuroster-
oidogenesis in the offspring hippocampus, with an increase in the gene
expression of P450(11β)-2, 11β-hydroxysteroid dehydrogenase type 2
and 17β- hydroxysteroid dehydrogenase type 1 and a decrease in StAR,
TSPO and 17β- hydroxysteroid dehydrogenase type 3 (Ohashi et al.,
2015). However, the possible sex specific effects of these molecules
remain to be determined.
3. Neuroactive steroid levels under pathological conditions
3.1. Alzheimer’s disease
Recent studies indicate that different neuropathological events af-
fect the synthesis and levels of neuroactive steroids. For example, al-
tered levels of neuroactive steroids as well as of neurosteroidogenic
enzymes are detected in post-mortem brain tissue of Alzheimer’s dis-
ease (AD) patients (Hasanpour et al., 2018; Luchetti et al., 2011a;
Luchetti et al., 2011b; Marx et al., 2006; Rosario et al., 2011; Yue et al.,
2005). Changes in brain neuroactive steroid levels have been detected
also in AD mouse models, such as the 3xTg-AD mouse, in which the
levels of dihydroprogesterone (DHP), its metabolite isopregnanolone
and 17beta-estradiol (17β-E) are significantly increased in the limbic
region compared to wild type mice (Caruso et al., 2013a). In addition,
the bilateral injection of amyloid β 25–35 into the hippocampal CA1
region induces a decrease in PREG and PROG levels as well as an in-
crease in 17β-E levels in this brain area. Altered levels of PROG and
17β-E in the prefrontal cortex are also detected in this animal model
(Liu et al., 2013).
3.2. Parkinson’s disease
A decrease of DHP has been reported also in the CSF of Parkinson's
disease (PD) patients (di Michele et al., 2003). In addition, the ex-
pression of the 5α-R type 1 enzyme is downregulated in the substantia
nigra, while that of 3α-HSOR type 3 is upregulated in the caudate nu-
cleus of PD patients (Luchetti et al., 2010). Neuroactive steroid levels
are also altered in PD rodent models. For instance, the total brain levels
of dihydrotestosterone (DHT) are increased by injection with 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (Bourque et al., 2016), while the
striatal levels of PREG and DHP are decreased and those of iso-
pregnanolone increased, by injection with 6-hydroxydopamine
(Melcangi et al., 2012).
3.3. Multiple sclerosis
Effects of Multiple Sclerosis (MS) on neurosteroidogenesis in hu-
mans are suggested by the demonstration that the expression of ar-
omatase and of 3β-HSD is increased respectively in MS lesions of male
and female MS patients (Luchetti et al., 2014). In addition, altered le-
vels of neuroactive steroids are detected in MS patients. For instance,
increased levels of PREG, isopregnanolone and 5α-androstane-3α,17β-
diol (3α-diol), and decreased levels of DHP, DHT, tetra-
hydroprogesterone (THP) and 17β-E have been detected in the CSF of
Relapsing Remitting (RR)-MS male adult patients (Caruso et al., 2014).
THP levels are also significantly decreased in brain samples of male MS
patients (Noorbakhsh et al., 2011). In addition, as recently observed in
brain tissue of MS patients and of experimental autoimmune en-
cephalomyelitis (EAE) mouse model, the pathology induces a decrease
in the levels of DHEA and in the expression of its synthesizing enzyme
Fig. 2. Sex differences in the levels of neuroac-
tive steroids in physiological conditions.
Neuroactive steroid levels in different compart-
ments of male and female rats. Higher level in
females (pink box) or in males (light blue box)
with respect to the other sex. Pregnenolone
(PREG) levels in the cerebrospinal fluid (CSF),
hippocampus, cerebral cortex and cerebellum
are higher in males than in diestrus females
(data in other phases of the estrous cycle are not
available). On the contrary, levels of this neu-
roactive steroid in plasma, spinal cord and
sciatic nerve are higher in diestrus females than
in males. The levels of its metabolite, proges-
terone (PROG), are higher in the male cerebral
cortex and cerebellum, while its CSF levels are
higher in diestrus females. Higher levels of the
PROG metabolite, dihydroprogesterone (DHP),
are detected in plasma, hippocampus, cerebral
cortex, cerebellum, spinal cord and sciatic nerve
of diestrus females compared to males.
Similarly, in plasma, hippocampus, cerebral cortex and sciatic nerve, the levels of the DHP metabolite, tetrahydroprogesterone (THP) also known as allopregna-
nolone, are higher in diestrus females, while in the CSF the levels of THP are higher in males. The levels of another metabolite of DHP, isopregnanolone, are higher in
the CSF, plasma, cerebral cortex, cerebellum and spinal cord of females, while in the sciatic nerve isopregnanolone levels are higher in male animals. The levels of
androgenic precursor dehydroepiandrosterone (DHEA), show higher levels in CSF, hippocampus, cerebral cortex and sciatic nerve of females but those of testosterone
(T) and dihydrotestosterone (DHT) are higher in plasma, CSF, CNS areas and sciatic nerve of male animals. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
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(i.e., CYP17A1) (Boghozian et al., 2017).
The brain levels of other neuroactive steroids, such as PREG and
PROG are also affected in EAE rat at the acute and chronic phases of the
disease (Caruso et al., 2010a; Giatti et al., 2010). It is important to
highlight that the observed effects on PREG levels are not detected in
plasma, suggesting a specific effect of EAE on neurosteroidogenesis
(Caruso et al., 2010a; Giatti et al., 2010).
The hippocampus and cerebral cortex show decreased expression
levels of StAR, P450scc and 5α-R in a demyelination mouse model in-
duced by the injection of cuprizone (Leicaj et al., 2018). Neuroactive
steroid levels are also altered in an experimental model of amyotrophic
lateral sclerosis. Thus, in male wobbler mouse, the levels of PROG, DHP
and THP are increased in the brain and spinal cord in association with a
decrease in testosterone (T) levels (Gonzalez Deniselle et al., 2016).
3.4. Traumatic CNS injury and stroke
Traumatic brain injury (TBI) in rodents modifies the brain levels of
PREG, PROG, THP, isopregnanolone, T, DHT and 17β-E (Lopez-
Rodriguez et al., 2015; Lopez-Rodriguez et al., 2016; Meffre et al.,
2007). Spinal cord transection also affects neuroactive steroid levels.
Indeed, an increase in PREG, PROG and its metabolites, DHP and THP,
is observed in the injured spinal cord of adult male rats (Labombarda
et al., 2006b). In addition, altered neuroactive steroid levels have been
also reported in stroke and ischemia models. Levels of PROG and of its
metabolite, DHP, are significantly increased by six hours after middle
cerebral artery occlusion in mice (Liu et al., 2012). In addition, the
levels of 17β-E are increased in hippocampal reactive astrocytes in a
global cerebral ischemia model (Zhang et al., 2014).
3.5. Peripheral neuropathy
The levels of neuroactive steroids are also affected in peripheral
nerves by diabetes (i.e., diabetic peripheral neuropathy) (Giatti et al.,
2018b; Pesaresi et al., 2011a; Pesaresi et al., 2010b), crush injury
(Roglio et al., 2008), and Charcot-Marie-Tooth disease type 1A
(CMT1A) (Caruso et al., 2008) in animal models. In addition, altered
levels of neuroactive steroids have been observed in peripheral nerve of
sterol regulatory element binding protein-1C knockout mice (Mitro
et al., 2017), which exhibits peripheral neuropathy (Cermenati et al.,
2015).
3.6. Diabetic encephalopathy
In addition to the well-characterized effects of diabetes on periph-
eral nerves and the retina, brain function may also be altered in this
pathology. Diabetic encephalopathy induces also changes in the levels
of neuroactive steroids in animal models (Calabrese et al., 2014; Giatti
et al., 2018b; Pesaresi et al., 2010a; Pesaresi et al., 2010b). Interest-
ingly, a reduction in PREG levels in the hippocampus, but not in
plasma, was reported in an experimental model of type 1 diabetes (i.e.,
by injection of streptozotocin), suggesting a direct effect of diabetes on
neurosteroidogenesis (Romano et al., 2017). This concept is supported
by the decreased expression of StAR and P450scc, the alteration in the
synthesis and metabolism of cholesterol, the substrate for ster-
oidogenesis, and the impaired functionality of mitochondria (i.e., the
subcellular organelles where PREG synthesis occurs) in the hippo-
campus of this animal model (Romano et al., 2017). It is interesting to
highlight that diabetes has specific effects on neurosteroidogenic me-
chanisms depending on the brain region considered. Indeed, the same
analysis performed in cerebral cortex showed that, even if also in this
brain area the decrease of PREG is associated with alteration in cho-
lesterol homeostasis and mitochondrial functionality, the mechanisms
responsible of these effects are different (Romano et al., 2018).
3.7. Affective and psychiatric disorders
Affective and psychiatric disorders, like for instance depression,
anxiety, premenstrual dysphoric disorder, postpartum depression,
posttraumatic stress, schizophrenia and impulsive aggression, also af-
fect the levels of neuroactive steroids (Backstrom et al., 2014; Maguire,
2019; Marx et al., 2011; Marx et al., 2009; Romeo et al., 1998;
Rupprecht et al., 2010; Schule et al., 2014; Uzunova et al., 1998). Es-
tradiol-withdrawal, monoamines and neural plasticity seems to have a
role in depressive responses (Frokjaker et al., 2015; Galea et al., 2001;
Sacher et al., 2010). In addition, anxiety-like behavior and depression
are mainly associated with decreased plasma and/or CSF levels of the
5α-reduced metabolites of PROG and T, which are able to interact with
GABA-A receptor (Frye et al., 2008; Maguire, 2019; Romeo et al., 1998;
Rupprecht and Holsboer, 1999; Rupprecht et al., 2010; Schule et al.,
2014; Walf and Frye, 2012). In agreement, the expression levels of 5α-R
type 1 enzyme are downregulated in prefrontal cortex Brodmamn’s area
9 of depressed patients (Agis-Balboa et al., 2014). A relationship be-
tween T levels and depression has been reported in both men (McHenry
et al., 2014; McIntyre et al., 2006; Shores et al., 2004) and women
(Kumsar et al., 2014) and a significant association between single nu-
cleotide polymorphisms rs523349 (Leu89Val) located in SRD5A2 gene
encoding 5α-R type 2 and autism has been also reported (Zettergren
et al., 2013).
An extensive literature is also available for the effects of ethanol on
neuroactive steroid levels and neurosteroidogenesis in humans (Finn
and Jimenez, 2018; Porcu et al., 2016; Ramachandran et al., 2015).
Indeed, plasma levels of THP are decreased in human alcoholics during
alcohol withdrawal and return to normal levels upon recovery (Romeo
et al., 1996). In agreement, risk of alcohol dependence is associated
with polymorphic variation in the enzymes 5α-R and 3α-HSOR
(Milivojevic et al., 2011).
Modifications in the levels of neuroactive steroids have been de-
tected also in male rodents showing depressive-like behavior after ex-
posure from preconception until lactation to bisphenol A, an endocrine
disruptor. In particular, these animals show decreased plasma levels of
DHEA (Xin et al., 2018). In addition, knockout mice for 5α-R type 2
enzyme show reduced dominance-related behaviors, as well as deficits
of novelty-seeking and risk-taking responses (Mosher et al., 2018).
3.8. Other disorders
Changes in neuroactive steroid levels have been also recently re-
ported in migraine and cluster headache. Indeed, THP plasma levels are
increased in episodic or chronic migraine and reduced in cluster
headache, while the levels of DHEA and its sulfate form are reduced in
the plasma of patients affected by chronic migraine (Koverech et al.,
2019).
Medication used to treat pain or to induce anesthesia may also affect
the levels of neuroactive steroids. For instance, in primary culture of
cortical neurons, ketamine increases the levels of T and decreases the
levels of 17β-E (Li et al., 2016), while in cultures of rat neural stem
cells, morphine treatment increases the levels of DHT and 17β-E (Feizy
et al., 2016) as well as the expression of 5α-R and aromatase
(Abdyazdani et al., 2017).
4. Influence of sex on neurodegenerative and psychiatric
disorders
4.1. Sex differences in the incidence of the disease
Several neurodegenerative and psychiatric disorders show sex dif-
ferences in incidence. For instance, the incidence of AD (Andersen
et al., 1999; Fratiglioni et al., 1997) and MS (Dooley and Hogan, 2003;
Gleicher and Barad, 2007; Jacobson et al., 1997) is higher in females,
while that of PD (Benito-Leon et al., 2003; de Lau et al., 2004; Van Den
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Eeden et al., 2003; Wooten et al., 2004) and stroke (Reeves et al., 2008;
Turtzo and McCullough, 2008) is higher in males. However, in stroke,
after 85 years of age, the incidence in the two sexes is the opposite
(Rosamond et al., 2007).
The incidence of autism is higher in boys than in girls (Fombonne,
1999, 2003). Depressive disorders (Hankin and Abramson, 1999), an-
xiety disorders (Afifi, 2007; Foot and Koszycki, 2004), including social
phobia, post-traumatic stress disorders, panic disorders, as well as
eating disorders (Kaye, 2008), such as anorexia and bulimia, are more
frequent in females than in males.
Diabetic encephalopathy is associated with cognitive deficits and
increased risk of dementia, stroke, cerebrovascular disease, AD and
psychiatric disorders, such as depression and eating disorders, which, as
mentioned above, show sex-specific features (Biessels et al., 2008;
Biessels et al., 2002; Gispen and Biessels, 2000; Jacobson et al., 2002;
Kodl and Seaquist, 2008). Therefore, diabetic encephalopathy shows
sex differences in the incidence, progression and severity, depending on
the associated pathology (Andersen et al., 1999; Farace and Alves,
2000; Fratiglioni et al., 1997; Kaye, 2008; Marcus et al., 2008; Niemeier
et al., 2007; Simonds and Whiffen, 2003). For instance, boys, but not
girls, with type 1 diabetes perform poorly in school compared to
healthy classmates, showing reduced performance and intelligence
quotient (Schoenle et al., 2002). In addition, females with type 2 dia-
betes have smaller hippocampal volumes in comparison to male pa-
tients (Hempel et al., 2012).
The incidence of PNS alterations shows also sex differences. For
instance, females are more predisposed than males to peripheral neu-
ropathy associated with chronic alcoholism (Ammendola et al., 2000).
In contrast, diabetic peripheral neuropathy is more frequent in men
than in women (Basit et al., 2004; Booya et al., 2005).
4.2. Sex differences in the manifestation of the pathological alterations
4.2.1. Alzheimer’s disease
Sex differences are not only observed in the incidence of neurode-
generative and psychiatric disorders but also in their neurological
outcomes. For instance, in AD, sex influences β-amyloid plaque dis-
tribution in the human temporal cortex (Kraszpulski et al., 2001) and β-
amyloid deposition in the brain of AD transgenic mice (Callahan et al.,
2001; Lewis et al., 2001). Analysis of visuospatial episodic memory in
AD patients shows better performance in men than in women (Beinhoff
et al., 2008). However, in an experimental model of AD (i.e., 3xTg-AD
mice), female animals perform worse than males at 6months of age
(Clinton et al., 2007).
4.2.2. Parkinson’s disease
In PD, women tend to be older than men at symptom onset and have
more a tremor dominant form of disease, which in turn is associated
with a slower disease progression (Haaxma et al., 2007). In experi-
mental models of this disease, male animals show higher depletion of
dopamine than females and also the pattern of proinflammatory mo-
lecules show sex differences (Czlonkowska et al., 2006).
4.2.3. Multiple sclerosis
Most commonly MS female patients show relapsing-remitting-type
symptomatology and the course of the disease is more benign in com-
parison to men (Hawkins and McDonnell, 1999), which are affected in
older age and develop a more severe pathology, reaching faster a severe
disability (Confavreux et al., 2003), with more destructive lesions than
women (Pozzilli et al., 2003). Cognitive decline is also more pre-
dominant in men than in women (Parmenter et al., 2007; Savettieri
et al., 2004). Inflammatory responses show also sex differences in MS
patients (Moldovan et al., 2008; Pelfrey et al., 2002) as well as in an-
imal models (Bebo et al., 1999a; Matarese et al., 2001; Reddy et al.,
2005). Observations in EAE model suggest also a sex difference in
markers of myelination, such as myelin basic protein (MBP) and
platelet-derived growth factor alpha receptor (PDGFαR), in spinal cord
(Massella et al., 2012).
4.2.4. Traumatic CNS injury and stroke
TBI results in higher mortality and poor outcomes in females than in
males (Farace and Alves, 2000; Kraus et al., 2000; Ng et al., 2006).
However, other studies suggest that women have better overall re-
sponses to rehabilitation therapy (Groswasser et al., 1998), better per-
formance on cognitive outcome measures (Ratcliff et al., 2007), and
that men have greater level of injury (Slewa-Younan et al., 2004). In
females, the outcomes of moderate-to-severe TBI are significantly better
after menopause, but not before menopause, in comparison to men
(Davis et al., 2006). In addition, the CSF of female patients show
smaller oxidative damage load than males after TBI (Wagner et al.,
2004). However, women have a poorer recovery from stroke than men
(Holroyd-Leduc et al., 2000; Kapral et al., 2005; Niewada et al., 2005;
Reeves et al., 2008; Roquer et al., 2003; Turtzo and McCullough, 2008).
Although some studies suggest increased long-term mortality in females
in comparison to males, other studies indicate the opposite (Devroey
et al., 2003; Eriksson et al., 2008; Kimura et al., 2005; Reeves et al.,
2008; Rosamond et al., 2007; Turtzo and McCullough, 2008).
In animal models of stroke, adult females show reduced lesions than
adult males, but this difference reverts with aging (Alkayed et al., 1998;
Hall et al., 1991; Manwani et al., 2013; Selvamani et al., 2014). Sex
differences have been also observed in the epigenetic modifications of
astrocytes after cerebral ischemia (Chisholm et al., 2015; Chisholm and
Sohrabji, 2015).
4.2.5. Peripheral neuropathy
Diabetic peripheral neuropathy also shows sex differences. For in-
stance, male diabetic patients develop this secondary effect of diabetes
earlier than female patients (Aaberg et al., 2008). In addition, male
patients show with higher frequency muscle weakness and atrophy
(Kiziltan and Benbir, 2008), as well as motor nerve conduction ab-
normalities, ulnar nerve involvement (Kiziltan and Benbir, 2008;
Kiziltan et al., 2007), lower amplitudes and conduction velocities and
longer latencies with respect to female patients (Albers et al., 1996). On
the contrary, female patients show more often neuropathic pain and
negative sensory symptoms (Kiziltan and Benbir, 2008). Observations
in the STZ-experimental model indicate the same sex specific effects
(Joseph and Levine, 2003). Interestingly, short-term diabetes in STZ rat
model affects axonal transport and mitochondrial function in male, but
not in female animals (Pesaresi et al., 2018). As reported in an ex-
perimental model of type 2 diabetes, such as BTBR ob/ob mice, in-
traepidermal nerve fiber loss is higher in males than in females (O'Brien
et al., 2016). A possible explanation might be the more robust increase
in metabolic perturbations (i.e., hypertriglyceridemia) observed in male
animals (Hudkins et al., 2010; O'Brien et al., 2016). Observations per-
formed in db/db mice (i.e., a genetic model of type 2 diabetes) also
support a higher peripheral neurovascular dysfunction in males (Fan
et al., 2018).
4.2.6. Diabetic encephalopathy
Short term diabetes in the streptozotocin (STZ) experimental rat
model induces a decrease of alpha 1 subunit of Na+, K+-ATPase in the
cerebellum of male, but not female rats. In contrast, long-term diabetes
causes a decrease in the expression of this subunit only in females
(Kalocayova et al., 2017). In db/db mouse, males develop a greater
extent of cognition deficits than females (Fan et al., 2018) and in the
same diabetic animal model, experimental stroke induces a higher
mortality and bigger infarction size in males than in females (Vannucci
et al., 2001). However, in an another experimental model of type 2
diabetes, such as the KKAy mouse model, ischemic brain injury induces
a much larger ischemic area as well as higher cerebral NADPH oxidase
activity in females in comparison to males (Sakata et al., 2011). In this
experimental model, female animals also show higher impairment in
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cognitive function, greater insulin resistance, lower expression of per-
oxisome proliferators-activated receptor gamma and higher superoxide
production (Sakata et al., 2010). In Goto-Kakizaki rats (i.e., a non-obese
model that spontaneously develops type 2 diabetes), middle-aged fe-
males were less vulnerable than males to oxidative damage and less
prone to the accumulation of AD-like neuropathological markers
(Candeias et al., 2017).
4.2.7. Affective and psychiatric disorders
Autistic male patients are more susceptible to alterations in genes
related with synaptic plasticity (Mottron et al., 2015). In a rat model of
autism, such as that induced by the prenatal exposure to valproic acid,
males show lower sensitivity to pain, elevated anxiety, decreased level
of social interactions, decreased thymus weight, decreased splenocyte
proliferative response to mitogenic stimulation, increased production of
NO by peritoneal macrophages and increased basal level of corticos-
terone in comparison to females (Schneider et al., 2008). In another
experimental model of autism, the reeler mice, heterozygous males at
variance to females, show a reduced number of Purkinje cells
(Doulazmi et al., 1999; Hadj-Sahraoui et al., 1996).
Even if the incidence of schizophrenia is comparable in men and
women, males usually experience the first onset of schizophrenia be-
tween 15 and 24 years, 3–4 years earlier than females. In addition, fe-
males may experience schizophrenia at the beginning of the menopause
(Hafner, 2003; Halbreich and Kahn, 2003; Rao and Kolsch, 2003;
Riecher-Rossler and Hafner, 2000). Generally, males show more severe
negative symptoms, but paranoid and disorganized subtype of the dis-
ease is more predominant in females (Goldstein and Link, 1988;
Moriarty et al., 2001). Moreover, antipsychotic and electroconvulsive
therapies are more effective in women than in men (Bloch et al., 2005;
Szymanski et al., 1995). Furthermore, women perform better on tests of
attention, verbal memory and executive function, while men perform
better on tests of spatial memory and visual processing (Goldstein,
2006; Goldstein et al., 1998; Seidman et al., 1997). Sex differences in
brain structures in schizophrenic patients have also been reported
(Andreasen et al., 1990; Andreasen et al., 1994; Bryant et al., 1999;
Goldstein et al., 2007; Goldstein et al., 2002; Gur et al., 2004; Pariante
et al., 2004; Reite et al., 1997; Takahashi et al., 2003). For instance,
schizophrenic male patients have larger ventricles and smaller frontal
and temporal lobe volumes (Andreasen et al., 1990; Andreasen et al.,
1994; Bryant et al., 1999; Reite et al., 1997), while women have an
increased hypothalamic volume (Goldstein et al., 2007).
5. Sex differences in the levels of neuroactive steroids under
pathological conditions
Observations in patients (Fig. 3) and in experimental models of
neurodegenerative and psychiatric disorders have shown sex-specific
alterations in neuroactive steroid levels and are here summarized.
5.1. Alzheimer’s disease
The neuroactive steroid environment could be one of the factors
that contribute to the sex differences reported in the incidence and/or
manifestation of neurodegenerative and psychiatric disorders. Several
recent observations, obtained from different laboratories, seem to
support this concept. For instance, as reported by a recent meta-ana-
lysis, low plasma T levels are significantly associated with increased
risk of AD in elderly men (Lv et al., 2016). In addition, higher free T
levels in females are associated with lower cerebral Aβ positivity, while
in males delay the progression of neurodegeneration (Lee et al., 2017).
This is confirmed by assessment in postmortem brain tissue. Indeed, a
decrease in brain levels of T occurs in male AD patients while, not only
T but also 17β-E levels are decreased in females (Rosario et al., 2011). A
male/female comparison of the levels of neuroactive steroids in ex-
perimental models of AD is still necessary.
5.2. Parkinson's disease
To our knowledge, there is not available information on a male/
female comparison of neuroactive steroid levels in human or animal
models of PD.
5.3. Multiple sclerosis
Studies in EAE rodent model of MS have shown sex-specific effects
in the levels of neuroactive steroids in the CNS. Among other changes,
PREG levels are decreased in the cerebral cortex, cerebellum and spinal
cord of EAE Dark-Agouti (DA) male rats at the acute (i.e., 14 days post-
immunization) and chronic (i.e., 40 days post-immunization) phases of
the disease, but are not modified in female animals (Caruso et al.,
2010a; Giatti et al., 2010).
5.4. Traumatic CNS injury and stroke
Male TBI patients show lower plasma levels of T and PROG com-
pared with healthy patients, while female patients show in addition
lower plasma levels of estradiol (Zhong et al., 2019).
Neuroactive steroid plasma levels are also affected by acute is-
chemic stroke in a sex specific way. Thus, an increase in 17β-E plasma
levels occurs in women but not in men (Casas et al., 2017).
Sex-specific effects of CNS injury and stroke on neuroactive steroids
have been observed also in animal models. For instance, TBI in male
rats, results in an increase, after six hours, in PREG and PROG brain
levels and a decrease in T levels, while in pseudopregnant female rats
an increase of isopregnanolone levels occurs (Meffre et al., 2007).
Longer time of TBI in female mice (i.e., 24 h, 72 h and 2weeks) induces
a significant decrease in the brain levels of PROG (at all times con-
sidered), THP (after 72 h and 2weeks), isopregnanolone (after 24 h and
2weeks), T (after 24 h) and 17β-E (after 2 weeks) (Lopez-Rodriguez
et al., 2015). On the contrary, a decrease of PREG and DHT levels,
associated with an increase in T levels, is observed by 2weeks after TBI
in the brain of male mice (Lopez-Rodriguez et al., 2016).
In mice, gonadectomy in females, but not in males, increases is-
chemic stroke sensitivity. This effect is mediated by gonadal secretions,
as demonstrated by the use of the four core genotype mouse model, in
which the testes determining Sry gene is located in an autosome and
allows to differentiate between gonadal effects and chromosome effects
on sex differences (Manwani et al., 2015). Female astrocytes are less
susceptible than males to oxygen-glucose deprivation and this is prob-
ably due to an enhanced aromatase activity in these cells. Indeed, ex-
pression and activity of this enzyme is higher in female than in male
astrocytes. In addition, aromatase inhibitors, like for instance arimidex,
abolish the sex difference in oxygen-glucose deprivation-induced cell
death (Liu et al., 2007). Moreover, the cerebral levels of PROG and DHP
are rapidly upregulated in male, but not in female mice, in response to
ischemic stroke, as recently demonstrated in an experimental model of
middle cerebral artery occlusion (Zhu et al., 2017).
5.5. Peripheral neuropathy
To knowledge authors there is not available information on a male/
female comparison of neuroactive steroid levels in patients. However,
in animal models of diabetic peripheral neuropathy, long-term diabetes
(i.e., three months after the induction) induces a decrease of PREG, T,
DHT and 3α-diol levels in the male rat sciatic nerve, while in females a
decrease in the levels of PROG, THP and isopregnanolone occur
(Pesaresi et al., 2010b). Short-term diabetes (i.e., one month after the
induction) induces a different sex pattern of changes in the sciatic
nerve. Thus, in the nerve of male rat, T and DHT levels are decreased in
association with an increase in THP levels, while the levels of all neu-
roactive steroids assessed are unaffected in the female sciatic nerve
(Pesaresi et al., 2018). Diabetes also differentially affects the expression
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of steroidogenic enzymes in the PNS. For instance, the expression of
aromatase is altered by long-term diabetes in a sex specific way. Indeed,
the expression of this enzyme is increased in the sciatic nerve of female
but not of male rats (Burul-Bozkurt et al., 2010).
In an animal model of the Charcot-Marie-Tooth disease type 1A
(CMT1A) inherited peripheral neuropathy, sexual differences in the
levels of some neuroactive steroids have also been identified. Indeed,
the levels of isopregnanolone and 3α-diol are decreased in female and
male sciatic nerve, respectively (Caruso et al., 2008).
5.6. Diabetic encephalopathy
To our knowledge, there is not available information on a male/
female comparison of neuroactive steroid levels in diabetic patients.
However, in experimental model of diabetes, neuroactive steroid levels
in the brain are modified depending on the sex. For instance, an in-
crease in DHEA and T levels, in association with a decrease in 17β-E
levels, occur in the brain of female Goto-Kakizaki rats. On the contrary,
only an increase of T occurs in the male brain (Candeias et al., 2017).
The effects of diabetes on CNS neuroactive steroid levels also show
regional differences. Thus, PROG and isopregnanolone levels are de-
creased in the cerebellum of long-term diabetic female rats, but not in
the cerebellum of males, while the opposite occurs in DHP levels. In
addition, the levels of THP in the spinal cord are decreased in male
animals but not in females (Pesaresi et al., 2010b). Furthermore, T and
DHT levels are significantly decreased in male cerebral cortex, cere-
bellum and spinal cord of male but not of female animals (Pesaresi
et al., 2010b). In addition, sex-specific changes in the brain levels of
neuroactive steroids in diabetic rats show variations that depend on the
duration of the pathology. For instance, PREG levels decrease in the
cerebral cortex and hippocampus of male rats (Romano et al., 2017;
Romano et al., 2018) but not in females after short-term diabetes
(cerebral cortex: controls 1.19 ± 0.26 vs STZ 0.50 ± 0.20; hippo-
campus: controls 2.67 ± 0.43 vs STZ 2.86 ± 1.00; data were obtained
by LC-MS/MS and expressed as pg/mg of tissue ± SEM, n=6). After
long-term diabetes, the levels of this neuroactive steroids are decreased
in the cerebral cortex of both sexes (Pesaresi et al., 2010b).
Some neuroactive steroids show similar changes in the brain of male
and female diabetic animals. For instance, the levels of PROG show a
similar decrease in male (Romano et al., 2017; Romano et al., 2018)
and female cerebral cortex (controls 3.90 ± 0.71 vs STZ 0.48 ± 0.09;
data are expressed as pg/mg of tissue ± SEM, n=6, p= 0.0007, data
were obtained by LC-MS/MS and analyzed by Student’s t test) and
hippocampus (controls 3.84 ± 0.84 vs STZ 0.58 ± 0.13; data are ex-
pressed as pg/mg of tissue ± SEM, n= 6, p= 0.0034, data were ob-
tained by LC-MS/MS and analyzed by Student’s t test) after short-term
diabetes and in the cerebral cortex after long-term diabetes (Pesaresi
et al., 2010b), in spite of the fact that the plasma levels of this neu-
roactive steroid are significantly decreased in female short-term dia-
betic animals (controls 10.27 ± 1.63 vs STZ 1.38 ± 0.17; data are
expressed as pg/μl of plasma ± SEM, n= 6, p=0.0003, data were
obtained by LC-MS/MS and analyzed by Student’s t test) but not in the
males (Romano et al., 2017; Romano et al., 2018). The decrease in
PROG plasma levels in diabetic female rats is in agreement with the
well-characterized alterations in the reproductive axis at the gonadal
and neuroendocrine levels in female diabetic patients (Giatti et al.,
2018b). Furthermore, the observed sex differences in plasma levels of
PROG in diabetic animals but not in the cerebral cortex and
Fig. 3. Sex differences in the levels of neuroactive steroids of patients under pathological conditions. Increase or decrease of neuroactive steroid levels in female (pink
box) or male (light blue box) patients in comparison to healthy subjects (*) or to the other sex (#). Alzheimer’s disease (AD): both T and 17β-estradiol (17β-E) levels
are decreased in the brain of female AD patients. Testosterone (T) levels are decreased in the brain of male AD patients. Traumatic brain injury (TBI): female patients
show lower plasma levels of T, progesterone (PROG) and 17β-E compared to healthy subjects. Male TBI patients show lower plasma levels of T and PROG compared
with healthy subjects. Stroke: 17β-E plasma levels are increased in women after stroke, but not in men. Schizophrenia: plasma levels of T are reduced in women with
stable multi-episode schizophrenia compared to healthy subjects. Decreased levels of pregnenolone (PREG) and dehydroepiandrosterone (DHEA) have been found in
the plasma of male schizophrenic patients. In addition, plasma levels of total T are reduced in stable multi-episode schizophrenia male patients. Major depressive
disorders (MDD): plasma levels of T are decreased in men with MDD. Posttraumatic stress disorders (PTSD): cerebrospinal fluid (CSF) levels of tetra-
hydroprogesterone (THP) are decreased in men with PTSD. Alcohol use disorder: THP immunoreactivity is increased in the substantia nigra pars medialis (pmSN) of
men with alcohol use disorder. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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hippocampus indicate that sex differences in peripheral steroid levels
induced by diabetes do not necessarily reflect similar sex differences in
the brain. Indeed, diabetes affects the expression of steroidogenic en-
zymes in the brain in a sex specific way. Thus, the expression of ar-
omatase is increased in the hippocampus of female but not of male rats
(Burul-Bozkurt et al., 2010).
5.7. Affective and psychiatric disorders
Men with major depressive disorder show lower T plasma levels,
while the levels of this neuroactive steroid in women are unaffected
(Giltay et al., 2017). In addition, studies in patients with posttraumatic
stress disorders have shown a decrease in the CSF levels of THP that are
associated with an impairment of 3α-HSOR in females (Rasmusson
et al., 2006) and of 5α-R in males (Rasmusson et al., 2019).
To our knowledge, there is not available information on a male/
female comparison of neuroactive steroid levels in autism. However,
sex differences have been detected in the levels of neuroactive steroids
in plasma of schizophrenic patients. In particular, the plasma levels of
PREG and DHEA are significantly decreased in male, but not in female
patients (Huang et al., 2017). In addition, a recent meta-analysis in-
dicates that plasma levels of total T are reduced in stable multi-episode
schizophrenia male patients and increased in female patients (Misiak
et al., 2018).
It has been ascertained by a recent postmortem study that THP
immunoreactivity in substantia nigra pars medialis, but not in other
brain regions, is significantly higher in men than in women diagnosed
with alcohol use disorder (Hasirci et al., 2017). Alcohol exposure
during fetal life also affects the levels of neuroactive steroids with sex
differences. For instance, sex differences occur in white matter micro-
structure in children and adolescent affected by prenatal alcohol ex-
posure, with girls and boys exhibiting lower and higher fractional an-
isotropy in brain white matter, respectively, compared to control
individuals (Uban et al., 2017). A relationship with neuroactive steroids
also occurs in these patients. Indeed, a positive association between
fractional anisotropy and T or DHEA levels is observed in girls, but not
in boys, with prenatal alcohol exposure (Uban et al., 2017).
It is known that alterations in the stress system are related with
depressive disorders (Maguire, 2019; Maydych, 2019; Park et al., 2019;
Patel et al., 2019) and recent evidence suggests that neuroster-
oidogenesis may contribute to sex differences in the stress axis. Low
levels of T in males and low levels of 17β-E and PROG in females are
associated with increased depressive-like behaviors in rodents
(Calmarza-Font et al., 2012; Diz-Chaves et al., 2012; Lagunas et al.,
2010; Osborne et al., 2009; Walf and Frye, 2010, 2014; Walf et al.,
2009). In addition, sex (with higher response in female animals) and
brain regional differences in the neuroactive steroid levels, and parti-
cularly in the 5α-reduced metabolites, occur after acute stress in rats
(Sze et al., 2018). For instance, the levels of DHP increase in the frontal
cortex and brainstem of male and female rats following stress. In ad-
dition, a significant increase in the levels of these neuroactive steroids is
also detected in the hypothalamus, amygdala and hippocampus in fe-
males, but not in males. Furthermore, the levels of THP, a metabolite of
DHP, are increased in all female brain regions analyzed, but only in the
frontal cortex of male animals (Sze et al., 2018). Interestingly, short-
term treatment of rats with an antidepressant drug such as fluoxetine
(i.e., a selective serotonin reuptake inhibitor), increases THP levels in
the brain of females, but not in the brain of males. This effect seems to
be due to an inhibition of THP retro-conversion into DHP (Fry et al.,
2014).
Stressful conditions not only cause sex differences in brain neu-
roactive steroid levels, but also differentially affect the expression of
brain steroidogenic molecules in males and females. For instance, en-
vironmental stress in rats caused by artificial light, immobility in a
small space and excessive heat, results in increased gene expression and
protein levels of 5α-R type 2 enzyme in the brain of adult males, but
decreased expression in females (Sanchez et al., 2009).
THP levels are decreased in the male, but not in the female brain in
a mouse model of autism spectrum disorder-like behavior induced by
the treatment with SKF105111, an inhibitor of the enzyme 5α-R type 1
and 2 (Ebihara et al., 2017). In another experimental model of autism
(i.e., the heterozygous reeler mouse) the levels of T and 17β-E are in-
creased, while the levels of DHT are decreased, at postnatal day 5 in the
male, but not in the female cerebellum (Biamonte et al., 2009).
In mice, exposure to predator odor stress (i.e., an experimental
model of traumatic stress) increases ethanol intake and has a synergistic
interaction with prior binge drinking in a sexually specific way (i.e., in
male but not in female animals) (Devaud et al., 2018). Interestingly, in
this experimental model brain regional and sex differences occur in
neurosteroidogenesis and in neuroactive steroid levels. For instance,
expression of P450scc in the prefrontal cortex is significantly decreased
in males, but increased in females, vs the corresponding controls. On
the contrary, the expression of this enzyme in hippocampus is increased
in females but not in male animals (Devaud et al., 2018). Assessment of
plasma neuroactive steroids shows a significant increase in the levels of
PREG and DHEA in male but not in female animals (Devaud et al.,
2018).
5.8. Other disorders
Sex specific features are also observed in association with mi-
tochondrial dynamin like GTPase (OPA1) mutations, which induce
degeneration of retinal ganglion cells (i.e., autosomal dominant optic
atrophy). As demonstrated in an animal model (i.e., OPA1delTTAG), the
levels of PREG and 17β-E are significantly increased in the retina and
plasma of female but not male animals in comparison to wild-type mice.
Interestingly, in retina of female OPA1delTTAG there is also an increase in
the expression of the steroidogenic molecules P450scc and 3β-HSD
(Sarzi et al., 2017), suggesting modifications in neurosteroidogenesis.
Gestational deficiency in methyl donors (e.g., vitamin B12 and fo-
late) produces hyperhomocysteinemia associated with impairment of
cerebellar synaptic plasticity and neurogenesis, together with cognitive
and motor disorders. This deficiency is associated with an impairment
of neurosteroidogenesis. Indeed, decreased levels of PREG and 17β-E
and expression of StAR and aromatase occur in the cerebellum of fe-
male rats, but not in males (El Hajj Chehadeh et al., 2014).
6. Neuroactive steroids as physiological modulators of neural
function
Neuroactive steroids act in the nervous system by binding to clas-
sical steroid receptors, such as PROG (PR), androgen (AR) and estrogen
(ER) receptors, as well as through non-classical steroid receptors, such
as G-protein coupled estrogen receptor (GPER), membrane-associated
protein PGRMC1 (also known as 25-Dx), the membrane PRs (mPR),
gamma-amino butyric acid (GABA) A and B receptors, N-methyl-D-as-
partate (NMDA) receptor, α-amino-3-hydroxy-5-methyl-4-iso-
xazolepropionic acid (AMPA) receptor, dopamine 1 (D1) receptor, the
nicotine receptors, the α-1 adrenergic receptor, the sigma-1 receptor
and L-type Ca2+ channels (Giatti et al., 2015a; Giatti et al., 2016b;
Hadjimarkou and Vasudevan, 2018; Singh et al., 2013; Vega-Vela et al.,
2017).
Neuroactive steroids regulate neural function during all life stages.
For instance, developmental actions of 17β-E include effects on neu-
rogenesis (Martinez-Cerdeno et al., 2006), neuronal survival (Chowen
et al., 1992), neuritogenesis (Arevalo et al., 2012a), synaptogenesis
(Bender et al., 2010) and differentiation of glial cells (Garcia-Segura
et al., 1989; McCarthy et al., 2008; McCarthy et al., 2003; Torres-
Aleman et al., 1992). PROG regulates the development of Purkinje cells
of the cerebellum (Tsutsui et al., 2011) and together with its metabo-
lites also modulates oligodendrocyte differentiation (Ghoumari et al.,
2005; Ghoumari et al., 2003; Jung-Testas et al., 1996), the myelination
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program (Guennoun et al., 2001; Magnaghi et al., 2007; Mercier et al.,
2001), the expression of myelin proteins (Ghoumari et al., 2003;
Melcangi et al., 2005; Melcangi et al., 1999) as well as myelin forma-
tion (Chan et al., 1998; Chan et al., 2000). T metabolites have similar
effects on myelin (Magnaghi et al., 2004; Magnaghi et al., 1999;
Melcangi et al., 2005).
During adult life, T, 17β-E and PROG act in specific brain regions to
regulate reproduction. Indeed, in males T acts as a negative regulator of
GnRH and LH pulse and frequency (Jackson et al., 1991; Steiner et al.,
1982), while in females 17β-E and PROG regulate GnRH pulsatility
(Skinner et al., 1998) and estrous responsiveness in the hypothalamus
(Barfield et al., 1984). These effects of PROG in females depend both on
its changes in plasma levels during the ovarian cycle and on its
synthesis by hypothalamic astrocytes after their stimulation by 17β-E
(Micevych and Sinchak, 2008).
T, 17β-E and PROG also regulate synaptic plasticity (Arevalo et al.,
2015b; Baudry et al., 2013; Foy et al., 2008; Frankfurt and Luine, 2015;
Garcia-Segura et al., 1994; Kramar et al., 2013; McEwen and Woolley,
1994; Murphy and Segal, 2000; Ooishi et al., 2012), cytoskeletal pro-
teins, the morphology of neurons and astrocytes (Garcia-Segura et al.,
1994; Guerra-Araiza et al., 2007; Kramar et al., 2013; Luquin et al.,
1993; Reyna-Neyra et al., 2002; Velazquez-Zamora et al., 2012), adult
neurogenesis (Bowers et al., 2010; Galea, 2008; Wang et al., 2008) and
cognition (Arevalo et al., 2015b; Celec et al., 2015; Colciago et al.,
2015; Frankfurt and Luine, 2015; Kramar et al., 2013; Velazquez-
Zamora et al., 2012). In addition, estrogens and androgens have com-
plementary effects on synaptic changes in the hippocampus. Thus, 17β-
E is responsible for the full expression of long-term potentiation, while
DHT for its conversion into long-term depression (Di Mauro et al.,
2015).
7. Neuroactive steroids as protective agents for the nervous
system
7.1. Estradiol, progesterone and progesterone metabolites
An extensive literature showing protective effects of neuroactive
steroids in several experimental models of CNS and PNS pathologies is
available. Indeed, 17β-E and PROG are protective in experimental
models of AD (Pike et al., 2009; Wang et al., 2008), PD (Bourque et al.,
2009; Callier et al., 2001; Rodriguez-Perez et al., 2013), Huntington’s
disease (Kumar et al., 2014; Tunez et al., 2006), epilepsy (Frye et al.,
2009; Frye and Scalise, 2000; Veliskova, 2006), excitotoxicity (Azcoitia
et al., 1999; Ciriza et al., 2006), stroke (Sayeed et al., 2007; Sohrabji,
2015), motoneuron degeneration (Gonzalez Deniselle et al., 2002;
Huppenbauer et al., 2005; Platania et al., 2005; Yu, 1989), MS and
demyelination (Garay et al., 2007; Garay et al., 2010; Ibanez et al.,
2003; Spence and Voskuhl, 2012; Taylor et al., 2010), TBI (Cutler et al.,
2007; Day et al., 2013; Djebaili et al., 2005; Lopez Rodriguez et al.,
2011) and spinal cord injury (Elkabes and Nicot, 2014; Labombarda
et al., 2006a; Mosquera et al., 2014; Siriphorn et al., 2012), among
others.
An important target of the neuroprotective effects of PROG is the
myelin compartment. For instance, this neuroactive steroid increases
MBP expression in a model of spinal cord injury (Labombarda et al.,
2006a; Labombarda et al., 2009) and promotes repair in the cuprizone
demyelinating experimental model, increasing the density of oligo-
dendrocyte progenitor cells and mature oligodendrocytes and the ex-
pression of proteolipid protein (PLP) and MBP (El-Etr et al., 2015).
PROG, administered together with 17β-E, also promotes MBP expres-
sion in this model (Acs et al., 2009).
Effects of PROG are in part mediated by its metabolites. Indeed,
both DHP and THP are protective against excitotoxicity (Ciriza et al.,
2006) and THP reduce seizures (Frye and Scalise, 2000) and protect
against stroke (Sayeed et al., 2006), oxygen-glucose deprivation
(Ardeshiri et al., 2006) and TBI (Djebaili et al., 2005). This neuroactive
steroid is also a potential candidate for the treatment of mood and
anxiety disorders (Wirth, 2011).
PROG and its derivatives are also able to counteract the damage
induced by the aging process on peripheral nerves. Indeed, these neu-
roactive steroids increase the expression of glycoprotein zero (P0) and
peripheral myelin protein 22 (PMP22) (Melcangi et al., 2003; Melcangi
et al., 1998; Melcangi et al., 2000b), and exert a beneficial effects on the
number and shape of myelinated fibers, reducing the frequency of
myelin abnormalities (Azcoitia et al., 2003; Melcangi et al., 2003).
Neuroprotective actions of PROG or DHP have been also reported in
different experimental models of peripheral nerve damage, such as
transection (Melcangi et al., 2000a), cryolesion (Koenig et al., 1995)
and guided regeneration of the facial nerve (Chavez-Delgado et al.,
2005), crush (Roglio et al., 2008) and docetaxel-induced peripheral
neurotoxicity (Roglio et al., 2009).
The metabolites of PROG also exert a variety of neuroprotective
effects in diabetic encephalopathy and diabetic peripheral neuropathy.
For instance, PROG and DHP counteract the decreased expression of
peripheral myelin proteins, such as P0 and PMP22 (Leonelli et al.,
2007) and the increase in the number of fibers with myelin infoldings in
the sciatic nerve of STZ diabetic rats (Veiga et al., 2006). In an ex-vivo
model of hyperglycemia (i.e., dorsal root ganglia cultures exposed to
high levels of glucose), these neuroactive steroids show similar pro-
tective effects (Giatti et al., 2018b). DHP also increases the expression
of another myelin protein, such as MBP, in the spinal cord of STZ
diabetic rats (Pesaresi et al., 2010a).
Lipid components of the peripheral myelin are also a target for the
protective effects of neuroactive steroids. Thus, DHP, by promoting
fatty acid desaturation altered by diabetes, reduces myelin structural
alterations in sciatic nerve (Mitro et al., 2014) and restores the lipid
profile of myelin in the cerebral cortex of STZ-rats (Cermenati et al.,
2017).
In STZ experimental model, PROG is also able to counteract the
increased CNS and PNS expression levels of vascular endothelial growth
factor, a marker of angiogenesis, interleukin-6, a marker of inflamma-
tion, and CD11, NG2, COX2 and matrix metalloproteinase-2, markers of
tissue injury (Atif et al., 2017). THP improves nerve conduction velocity
(NCV), thermal threshold and skin innervation density, while its pre-
cursor, DHP, in addition to these parameters, also improves alterations
in Na+,K+-ATPase activity (Leonelli et al., 2007). Other protective
effects of 17β-E, PROG and its metabolites include the regulation of
proapoptotic and anti-apoptotic proteins (Arevalo et al., 2015a; Djebaili
et al., 2005), the decrease of oxidative stress (Liu et al., 2011; Mosquera
et al., 2014; Ozacmak and Sayan, 2009; Zhang et al., 2009) and of lipid
peroxidation (Ishihara et al., 2014; Roof and Hall, 2000; Zhu et al.,
2012).
In addition, THP ameliorates diabetic-induced thermal hyperalgesia
and prevents cell apoptosis in spinal cord in the STZ model (Afrazi
et al., 2014). The mechanisms of action of neuroactive steroids on
neuropathic pain have been also characterized in other experimental
models (Mensah-Nyagan et al., 2009; Patte-Mensah et al., 2014), where
they regulate molecules involved in pain signaling, such as T-type
calcium channels, GABA-A channels, P2X3 receptors, voltage-gated
sodium channels and bradykinin signaling (Ayoola et al., 2014; Cho and
Chaban, 2012). The inhibition of the local synthesis of THP in the spinal
cord enhances neuropathic pain induced by sciatic nerve injury (Patte-
Mensah et al., 2014). In addition, this neuroactive steroid and its pre-
cursor, DHP, suppress neuropathic symptoms (allodynia/hyperalgesia)
evoked by antineoplastic drugs such as vincristine (Meyer et al., 2010)
and oxaliplatin (Meyer et al., 2011).
7.2. Androgens
Androgens are also neuroprotective agents. Indeed, T and DHT exert
protective effects in PD animal models (Bourque et al., 2009; Khasnavis
et al., 2013), in EAE models (Bebo et al., 1999b; Dalal et al., 1997;
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Giatti et al., 2015b; Palaszynski et al., 2004b), in MS patients (Kurth
et al., 2014; Sicotte et al., 2007) and in an experimental model of TBI
(Barreto et al., 2007). The effect of androgens on stroke is still unclear,
since both protective and deleterious effects have been reported
(Quillinan et al., 2014). A possible hypothesis is that the effect depends
on the dosage applied. Indeed, positive effects are obtained with low
doses and in middle-aged and older animals (Quillinan et al., 2014).
DHT is able to counteract the male hippocampal neuronal loss after
kainic acid injection (Ramsden et al., 2003). Moreover, T or DHT pro-
tect hippocampal neurons form apoptosis caused by β-amyloid, staur-
osporine, Apoptosis Activator II (Nguyen et al., 2010; Zhang et al.,
2004) or serum deprivation (Hammond et al., 2001). In experimental
models of AD, T decreases β-amyloid (Rosario et al., 2012) and reduces
pathological alterations (Rosario et al., 2010). In addition, T and DHT
are protective factors for motoneurons (Huppenbauer et al., 2005).
Androgens are also protective agents in the PNS. Thus, T and DHT
induce a faster regeneration and functional recovery of injured nerves
(Huppenbauer et al., 2005; Jones et al., 2001; Tanzer and Jones, 2004;
Vita et al., 1983; Yu, 1982) and its precursor, DHEA, decreases the
extent of denervation atrophy and induces an earlier onset of axonal
regeneration after sciatic nerve transection in rats (Ayhan et al., 2003).
In addition, DHT stimulates Na+,K+-ATPase activity and P0 expression
in the sciatic nerve of STZ diabetic rats (Roglio et al., 2007) and
counteracts the impairment of NCV, thermal sensitivity and skin in-
nervation density induced by diabetes (Roglio et al., 2007). In the same
experimental model, the further metabolite of DHT, 3α-diol, also im-
proves NCV, thermal sensitivity and skin innervation density (Roglio
et al., 2007) and reduces myelin structural alterations and the accu-
mulation of myelin saturated fatty acids in the sciatic nerve (Mitro
et al., 2014). In addition, the androgen precursor DHEA prevents neu-
ronal (Pesaresi et al., 2011b) and vascular dysfunction (Yorek et al.,
2002).
Androgens exert also beneficial effects on neuropathic pain occur-
ring in diabetes mellitus. For instance, in the STZ model, DHT coun-
teracts the effect of diabetes on mechanical nociceptive threshold while
3α-diol is effective on tactile allodynia (Calabrese et al., 2014).
8. Sex differences in the physiological and protective actions of
neuroactive steroids
8.1. Sex differences in the expression of steroid receptors
8.1.1. Physiological conditions
As mentioned above, neuroactive steroids may exert their effects by
classical and non-classical steroid receptors. Some observations indicate
the existence of sex differences in the pattern expression of these re-
ceptors. For instance, in developing primary hippocampal neurons, the
expression of ERs (ERα, ERβ and GPER) is higher in female cultures and
the expression of AR is higher in male cultures (Ruiz-Palmero et al.,
2016). In comparison to males, the expression of ERα is higher in the
bed nucleus of the stria terminalis and in the medial preoptic area of
female animals while that of AR is higher in the anteroventral peri-
ventricular nucleus, in the ventrolateral part of the ventromedial hy-
pothalamic nucleus and in the arcuate nucleus. In addition, a higher AR
expression is detected in the bed nucleus of the stria terminalis and in
the medial preoptic area of male animals (Brock et al., 2015). Further
observations indicate that during the perinatal period the gene ex-
pression of AR is higher in the hypothalamus and prefrontal cortex of
male animals. In addition, the expression of ERα is higher in the hy-
pothalamus and hippocampus of male animals before birth. On the
contrary, the gene expression of ERβ is higher in the prefrontal cortex of
female animals immediately after birth (Mogi et al., 2015). Kisspeptin 1
neurons of anteroventral periventricular nucleus express higher levels
of ERα and PR in females than in males (Poling et al., 2017). Classical
genomic effects of neuroactive steroids also imply coactivators, like for
instance the steroid receptor coactivator-1. Assessment of its
immunoreactivity in the rodent brain shows higher levels in males than
in females (Bian et al., 2011).
8.1.2. Pathological conditions
Sex specific changes in the pattern expression of steroid receptors
also occur under pathological conditions. For instance, as demonstrated
in MS patients, the expression of ERβ is increased in lesions of men,
while that of PR in those of women (Luchetti et al., 2014). In addition,
impairment in cerebellar synaptic plasticity and neurogenesis together
with cognitive and motor disorders observed in hyperhomocysteinemia
is associated with a decreased expression of ERα and ERβ in the rat
cerebellum of female rats (El Hajj Chehadeh et al., 2014).
8.2. Sex differences in the actions of neuroactive steroids under
physiological conditions
Among the variety of the physiological effects exerted by neuroac-
tive steroids, some of them show sex specific features. For instance, the
expression of the isoform PR-A is induced by 17β-E in the cerebellum of
male rats, but not in females (Guerra-Araiza et al., 2002). In addition,
treatments with 17β-E or DHT increase the gene expression and protein
levels of aromatase in female, but not in male neuronal cultures
(Cisternas et al., 2017).
The role of 17β-E on synaptic plasticity also shows sex specific
features in the hippocampus (Vierk et al., 2014; Vierk et al., 2012) and
basolateral amygdala (Bender et al., 2017). For instance, long term
potentiation in the hippocampus of female and male mice is impaired
by the systemic administration of an inhibitor of aromatase, but the
effect was particularly prominent in females (Vierk et al., 2012). In-
hibition of aromatase activity in the hippocampus also results in a de-
creased number of hippocampal synapses, but only in females (Vierk
et al., 2014; Vierk et al., 2012). In addition, systemic treatment with
letrozole (i.e., an inhibitor of aromatase) reduces spine synapse density
in basolateral amygdala of adult female but not of male animals and the
same occurs in organotypic corticoamygdalar cultures from immature
animals (Bender et al., 2017).
17β-E suppresses GABAergic inhibition in the hippocampus of fe-
males by a mechanism implying ERα, mGluR and endocannabinoid-
dependent mechanism. However, this does not occur in male animals
(Tabatadze et al., 2015). This neuroactive steroid also potentiates glu-
tamatergic synaptic transmission in the hippocampus, however the
mechanism involves distinct ER subtypes in each sex (Oberlander and
Woolley, 2016). A similar situation occurs for the effects of 17β-E on
hippocampal memory. Thus, actions of this neuroactive steroid in the
hippocampus exerts beneficial effects on memory consolidation in both
sexes, however at variance to what is observed in females, activation of
extracellular signal-regulated kinase is not necessary in male animals
(Koss et al., 2018).
Local synthesis of 17β-E also contributes to sex differences in
neuritogenesis. Indeed, neuronal synthesis of this neuroactive steroid
promotes higher expression of the neuritogenic factor Neurogenin 3
(Ngn3) and increased neuritogenesis in developing female primary
hippocampal neurons compared to male neurons. In contrast, treatment
with T or DHT increases the expression of Ngn3 and neuritogenesis in
male hippocampal neurons and reduced these parameters in female
neurons (Ruiz-Palmero et al., 2016).
As mentioned above, the myelin compartment is a target for PROG
and its metabolites. Interestingly, some effects exerted by these neu-
roactive steroids on PNS myelin proteins (i.e., P0, PMP22, MAG and
MAL) are sex specific (Magnaghi et al., 2006). In addition, sex differ-
ences in the effects of PROG have also been reported in Schwann cell
proliferation (Fex Svenningsen and Kanje, 1999). Finally, it is inter-
esting to note that, as recently demonstrated, the sex difference ob-
served in oligodendrocyte density and myelin proteins (Cerghet et al.,
2006) are related with a postnatal increase of androgens and AR sig-
naling (Abi Ghanem et al., 2017).
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8.3. Sex differences in the actions of neuroactive steroids under pathological
conditions
As mentioned above, several neuroprotective effects of neuroactive
steroids have been reported (see section 8). However, most of the stu-
dies present in the literature have been conducted only in one sex. Thus,
the possible influence of the sex in the protective effects of neuroactive
steroids in animal models of neurodegeneration and psychiatric al-
terations has been poorly considered so far. Some examples of sex
differences in the neuroprotective actions of neuroactive steroids are
discussed in the following sections (Fig. 4).
8.3.1. Parkinson’s disease
17β-E has been shown to reduce lesion size in a PD animal model,
but only in gonadectomized females. On the contrary, it increases da-
mage in gonadectomized males (Murray et al., 2003). Thus, in this
experimental model of PD, estrogens are neuroprotective in females but
neurotoxic in males (Gillies et al., 2004). In agreement, T enhances
dopamine depletion induced by methamphetamine in male, but not in
female animals (Lewis and Dluzen, 2008). Interestingly, the gene parkin
seems to have a role in the sex specific effects of 17β-E. Indeed, using
parkin null mice (i.e., an animal model of PD), some of the neuropro-
tective effects exerted by this neuroactive steroid disappear in this ex-
perimental model (Rodriguez-Navarro et al., 2008).
Neuroprotective effects of 17β-E on PD and other neurodegenera-
tive diseases may be also exerted by protection on mitochondria (Vina
et al., 2003). Indeed, as observed in sex specific cultures of rodent
mesencephalic neurons exposed to a mitochondrion-toxin such as 6-
OHDA (i.e., an in vitro model of PD), treatment with this neuroactive
steroid induces a more prominent neuroprotective effect (i.e., reduced
free radical production and cell death) in female than in male neurons
(Misiak et al., 2010).
8.3.2. Traumatic CNS injury and stroke
Numerous studies have shown that PROG exerts protective actions
after traumatic CNS injury in rodents. Sex differences in the neuro-
protective action of PROG have been reported in adolescent mice. Thus,
PROG promotes motor recovery in adolescent male, but not in female
mice after controlled TBI (Mannix et al., 2014).
Excitotoxicity is one of the main causes of secondary neuronal death
in traumatic CNS injury and stroke. In cultured hippocampal neurons,
DHT exerts a protective effect against apoptosis induced by glutamate
in male, but not female cells (Zup et al., 2014). A non-competitive
NMDA receptor-antagonist, such as MK801, produces a sex specific
neurotoxic effect (i.e., females are markedly more sensitive than males)
that is affected by neuroactive steroid treatment. Indeed, in gona-
dectomized male rats, either T or DHT reduce brain damage, while in
gonadectomized females only DHT is effective. In addition, in this
model DHT is partially protective in intact females while in males 17β-E
is neurotoxic. Thus, a possible conclusion could be that non-aromatiz-
able androgens are neuroprotective while estrogens counteract this ef-
fect (de Olmos et al., 2008).
The metabolite of PROG, THP, exerts dose-dependent sex-specific
neuroprotective actions in ischemic models. Indeed, a low dose of this
neuroactive steroid provides higher neuroprotection from ischemic
damage in females than in males, while a higher dose is beneficial in
both sexes (Kelley et al., 2011). As reported in an experimental model
of neonatal hypoxic/ischemic brain injury, treatment with PROG is
protective in males but not in female animals (Dong et al., 2018). Si-
milar sex differences have been reported in an animal model of neo-
natal hypoxic-ischemic encephalopathy (Peterson et al., 2015). In an
experimental model of hypercapnia-induced activation of the locus
coeruleus, 17β-E reduces the activation of noradrenergic neurons in
female but not in male rats (de Carvalho et al., 2016). Finally, in an
experimental model of type 2 diabetes (i.e., the KKAy mouse) female
Fig. 4. Sex dimorphic neuroprotective effects of neuroactive steroids in experimental models of neurodegenerative or psychiatric disorders. Female animals: tet-
rahydroprogesterone (THP) attenuates the hypothalamo-pituitary-adrenal axis responses to interleukin-1β in adult prenatally stressed female rats and is neuro-
protective in models of epilepsy and ischemia. Dehydroepiandrosterone (DHEA) is neuroprotective in models of diabetic peripheral neuropathy. Dihydrotestosterone
(DHT) is neuroprotective in models of neurotoxicity and 17β-estradiol (17β-E) is neuroprotective in models of epilepsy, hypercapnia, Parkinson’s disease and stroke.
Male animals: progesterone is neuroprotective in models of hypoxic-ischemic brain injury, traumatic brain injury, anxiety and fear. Testosterone is neuroprotective
against neurotoxicity and in models of anxiety and depression. DHT is neuroprotective against neurotoxicity and the DHT metabolite 3β-diol normalizes the
hypothalamo-pituitary-adrenal axis responses to interleukin-1β in adult prenatally stressed male rats. Finally, 17β-E shows higher antipsychotic effects in female
animals.
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animals exhibit a more severe ischemic brain damage after stroke than
males and 17β-E treatment induced an attenuation of oxidative stress
(Sakata et al., 2011).
8.3.3. Peripheral neuropathy
In a rat model of diabetes type 1 (i.e., STZ injection), gonadectomy
protects females, but not males, from diabetic peripheral neuropathy by
increasing DHEA levels in the sciatic nerve (Pesaresi et al., 2011a).
Indeed, the efficacy of the DHEA treatment was higher in gonadally
intact diabetic females than in intact diabetic males (Pesaresi et al.,
2011b).
8.3.4. Diabetic encephalopathy
DHEA may also alter in a sex-specific way the glucose metabolism in
the CNS. Thus, this neuroactive steroid decreases glucose uptake and
increases glycogen content in cerebral cortex and olfactory bulb of
male, but not of female animals (Vieira-Marques et al., 2017). In hy-
poglicemic animals, ERα and ERβ enhance astrocyte AMPK and gly-
cogen synthase expression together with an inhibition of glycogen
phosphorylase in female animals, while activation of ERβ suppresses
these proteins in male animals (Hasan Mahmood et al., 2018).
8.3.5. Affective and psychiatric disorders
Neuroactive steroids also show sex specific effects in psychiatric
disorders. For instance, in a model of schizophrenia, 17β-E shows an-
tipsychotic effect in both sexes, but is more effective in males than in
females (Arad and Weiner, 2010). The KO of GPER1 produces sex dif-
ferences in behavioral responses. Thus, GPER1 KO male mice express a
marked increase of exploratory drive in elevated plus maze and light-
dark choice test to variance of female animals that displayed a less
pronounced phenotype. Thus, this estrogen membrane receptor seems
to be involved in anxiety and stress control in a sex specific way
(Kastenberger and Schwarzer, 2014). In addition, as recently demon-
strated, endogenous T production in males plays an important role in
the sex differences in anxiety that have been reported in aged rats
(Domonkos et al., 2017). Indeed, several clinical and preclinical studies
suggest that T is strongly beneficial in males against anxiety and de-
pression (McHenry et al., 2014).
Amygdala-medial frontal cortex connections regulate anxiety as
well as fear. As recently demonstrated, PROG decreases the responsivity
to amygdala stimulation, particularly in males (Contreras and
Gutierrez-Garcia, 2017). Interestingly, a significant association of an-
xiety with two intronic single nucleotide polymorphisms (rs3930965
and rs41314625) located in the AKR1C1 gene, which plays an im-
portant role in the regulation of PROG effects (El-Kabbani et al., 2011),
has been reported in female patients with panic disorders (Quast et al.,
2014). In addition, the PROG metabolite THP attenuates in adult pre-
natally stressed rats the hypothalamo-pituitary-adrenal axis responses
to interleukin-1β only in females, while 3β-diol normalized these re-
sponses in males (Brunton et al., 2015). This neuroactive steroid is also
able in females, but not in males, to block the stress-induced re-
instatement of cocaine-seeking behavior induced by yohimbine (i.e., a
pharmacological stressor) (Anker and Carroll, 2010).
8.3.6. Other disorders
In an epilepsy animal model, 17β-E treatment reduces hippocampal
injury but only in ovariectomized females (Galanopoulou et al., 2003).
In addition, the PROG metabolite THP, shows greater antiseizure po-
tency in females than in males and this effect seems to be related with a
greater abundance of extrasynaptic δ-subunit of GABA-A receptors in
females (Reddy et al., 2019).
9. Targeting neurosteroidogenesis as a possible pharmacological
approach for neuroprotection
9.1. Translocator protein ligands
As mentioned above, neuroactive steroids represent promising
protective agents for neurodegenerative and psychiatric disorders. One
possible therapeutic strategy could be to induce neurosteroidogenesis
by ligands of TSPO. As shown in Fig. 1, TSPO is one of the component of
the molecular complex able to translocate cholesterol into mitochon-
dria. Although this protein may not be essential for steroidogenesis, it is
necessary for the proper regulation of the steroidogenic process
(Morohaku et al., 2014; Papadopoulos et al., 2018; Selvaraj and Stocco,
2015; Selvaraj et al., 2015). Thus, activation of TSPO stimulates PREG
synthesis and consequently increases neuroactive steroid levels
(Papadopoulos, 2014; Papadopoulos et al., 2018).
In addition, TSPO ligands regulate mitochondrial respiration, per-
meability transition pore opening, apoptosis and cell proliferation. On
the other hand, TSPO is also related with neuroinflammation (i.e., it is a
marker of microglial activation). Interestingly, total distribution vo-
lume of TSPO is related with the duration of untreated major depressive
disorder (Setiawan et al., 2018) and with first-episode psychosis and
schizophrenia (Plavén-Sigray et al., 2018). In addition, TSPO distribu-
tion shows sex differences in healthy patients (Tuisku et al., 2019).
Acting through the mechanisms mentioned above, some TSPO li-
gands exert a beneficial effect in different experimental models of
neuropathology (Arbo et al., 2015; Cheng et al., 2016; Da Pozzo et al.,
2015; Giatti et al., 2015a; Giatti et al., 2015c; Ishikawa et al., 2016;
Leva et al., 2017; Ma et al., 2016; Santoro et al., 2016). For instance,
TSPO activation ameliorates the behavioral deficits of post-traumatic
stress disorder (Miao et al., 2014) and protects from MS (Daugherty
et al., 2013), AD (Barron et al., 2013), diabetic encephalopathy (Mitro
et al., 2012), diabetic peripheral neuropathy (Giatti et al., 2009), aging-
induced peripheral neuropathy (Leonelli et al., 2005) and peripheral
nerve injury (Ferzaz et al., 2002; Girard et al., 2012; Girard et al.,
2008).
9.2. Liver X receptor ligands
Another possible strategy to increase neuroactive steroid levels and
consequently to exert protective effects is represented by activation of
the liver X receptors (LXRs). In adrenal glands, LXRs regulate StAR and
induce the expression of genes involved in cholesterol homeostasis
(Cummins and Mangelsdorf, 2006; Cummins et al., 2006). Protective
effects of the activation of LXRs have been reported in cerebral ischemia
(Cheng et al., 2010), MS, AD and PD (Xu et al., 2013). In addition, the
induction of neurosteroidogenesis associated to the neuroprotective
effects of LXR ligands has been reported in diabetic peripheral neuro-
pathy (Cermenati et al., 2010) and diabetic encephalopathy (Mitro
et al., 2012).
9.3. 5α-reductase inhibitors
As mentioned above 5α-R represents a key enzyme for the meta-
bolism of PROG and T. Therefore, inhibitors of this enzyme, such as
finasteride or dutasteride, exert beneficial effects in experimental
models of neurodegeneration. For instance, finasteride treatment exerts
neuroprotective effects in ischemic brain injury induced in aged male
rats (Tanaka et al., 2019), while dutasteride is protective in an ex-
perimental model of PD (Litim et al., 2015, 2017). In addition, several
observations suggest that these 5α-R inhibitors have therapeutic effi-
cacy in behavioral disorders and specifically those associated with do-
paminergic hyperfunction, such as Tourette syndrome and dyskinetic
manifestations (Bortolato et al., 2008; Fanni et al., 2019; Frau and
Bortolato, 2019). Finally, dutasteride reduces subsequent alcohol con-
sumption in subjects classified as heavy drinkers (Covault et al., 2014).
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Therefore, the pharmacological modulation of this enzyme may re-
present a useful therapeutic approach for alcoholism, as well as for
other neurological or psychiatric diseases. On this point of view, the
comparison, still lacking, of the effects in male and female subjects will
be extremely important. However, a word of caution is necessary for the
use of these inhibitors. Indeed, it is important also to highlight that
these 5α-R inhibitors may have, in case of androgenetic alopecia, ser-
ious endocrine and neuropsychiatric side effects, such as erectile and
ejaculatory dysfunctions, loss of libido, depression, anxiety, suicidal
thoughts and sleep problems, which may persist despite treatment
withdrawal (Giatti et al., 2018a; Irwig, 2012a,b; Traish et al., 2015).
Indeed, both clinical (Basaria et al., 2016; Caruso et al., 2015; Chiriaco
et al., 2016; Melcangi et al., 2013, 2017) and experimental studies
(Diviccaro et al., 2019; Giatti et al., 2016a) have recently supported the
existence of a so called “Post-Finasteride Syndrome”.
10. Neuroinflammation as a possible target for sex-specific
therapy based on neuroactive steroids
Immune surveillance of the CNS is a multifaceted dynamical process
based on the recruitment of different cells and structures in precise time
windows. Its peculiarity resides in the microenvironment of the CNS,
strictly ruled by anatomical barriers that separate the CNS from the
circulation. The blood brain barrier (BBB), the blood-CSF barrier and
the meninges provide a highly selective gateway for peripheral circu-
lating immune cells but also represent immunologically active niches
accommodating perivascular, choroid plexus and meningeal macro-
phages, together with dendritic cells (DCs) and granulocytes (Brown
and Weinberg, 2018; Herz et al., 2017). All these cells differently
contribute to both physiological and pathological pathways in a close
relationship with the resident microglia and astrocytes (Fig. 5).
Neuroinflammation is a common treat characterizing several dif-
ferent pathologies. Immune cell populations are differentially recruited
in function of the type of insult and play beneficial or detrimental roles
depending on the persistence of an aggressive phenotype M1/Th1, re-
garded as pro-inflammatory and that may potentially enhance tissue
damage, vs the M2/Th2 phenotype, which is considered im-
munomodulatory and pro-reparative (Mantovani et al., 2005).
Possibly, the most complex involvement of immune cells in the CNS
occurs in autoimmune diseases, of which MS is the most common.
Myeloid cells (macrophages, monocytes and dendritic cells) are among
the most prominent of the immune infiltrates in MS. These cells act in
concert with T-cells by attracting them to the CNS parenchyma and
contribute to lesion formation. In particular, myeloid cells located at
the perivascular and meningeal spaces recruit and reactivate infiltrating
autoreactive T-cells to undergo expansion and enter the parenchyma
(Brown and Weinberg, 2018). Moreover, release of inflammatory cy-
tokines alters the integrity of the BBB at an early stage of the disease
(Brown and Weinberg, 2018). Compared to aggressive monocytes, re-
sident microglia clear tissue debris and contribute to recovery, although
the phenotypic similarity with monocytes makes difficult to resolve
their behavior. The same difficulty is faced in neurodegenerative dis-
eases, where the immune contribution seems to essentially rely on
microglia, while the role of monocytes is questionable (Herz et al.,
2017).
Both microglia and myeloid cells contribute to repairing (i.e. pro-
moting angiogenesis, axonal regeneration) and/or to secondary de-
generation after CNS injury (Herz et al., 2017). It has been hypothe-
sized that the reconstructing or detrimental action of these immune
cells probably rely on timing and route of infiltration, whether from the
choroid plexus or blood vasculature, after injury (Herz et al., 2017).
Hormonal environment is one of the factors that determine sex
differences in the immune response. Indeed, in autoimmune diseases
such as MS, females represent the highest percentage of cases (Jacobson
et al., 1997), possibly due to reduced androgen levels. The observation
that MS onset occurs later in males than in females, in coincidence with
the decline in bioavailable T (Weinshenker, 1994), and that castration
of male mice increases EAE susceptibility, underline the sensitivity to T
modulation (Palaszynski et al., 2004b). Similar results are observed in
other autoimmune disorders such as rheumatoid arthritis, extending the
role of T to different autoimmune syndromes (Harbuz et al., 1995).
The presence of nuclear, membrane-bound and G-protein coupled
sex steroid receptors in lymphocytes and myeloid cells (Blasko et al.,
2009; Kovats et al., 2010) renders them sensitive to a wide plethora of
neuroactive steroids, beside T, indicating a complex sex-dependent
immune modulation under hormonal control. As such, androgens/T,
17β-E and PROG are known to influence the functioning of immune
cells in different pathological contexts.
10.1. Neuroimmune control by androgens
The experimental findings commented above suggest mainly an
anti-inflammatory role for T that is supported by observations obtained
in vitro and in vivo, both in animal models and in clinical studies. This
effect seems to be independent on the type of insult suffered from the
nervous system and involves different cell types recruited in the in-
flammatory response.
Reduction of pro-inflammatory profile towards an anti-in-
flammatory one has been observed upon androgens/T administration in
MS animal models (Bebo et al., 1999b; Dalal et al., 1997) and humans
(Gold et al., 2008), following TBI (Barreto et al., 2007; Garcia-Estrada
et al., 1993), and in animal models of neurodegenerative diseases
(Tomas-Camardiel et al., 2002; Yao et al., 2017).
Sex-dependent polarization in T-cell response is observed upon mice
immunization with encephalitogenic peptide so that T-cells from male
mice have a lower interferon-gamma (IFN-γ)/ interleukin-10 (IL-10)
ratio then T-cells from female mice (Bebo et al., 1999b). Female T-cells
show an inverse response, increasing IL-10 production over IFN-γ, upon
ex-vivo exposure to physiologic concentration of DHT or T (Bebo et al.,
1999b). Accordingly, T reduces differentiation of T-cells towards au-
toreactive pro-inflammatory Th1 and Th17 phenotype both in vivo in an
EAE model and in vitro in murine splenic T-cells under polarizing
conditions (Massa et al., 2017). These observations have a counterpart
at clinical level, where T treatment of male MS patients induces a shift
in peripheral lymphocyte composition by decreasing CD4+ T cell
percentage (TH1 phenotype) and increasing natural killer (NK) cells
(suggested to promote regulatory T-cells and enhance Th2-response)
(Gold et al., 2008).
Androgens can thus alter the development of effector T-cells and
may play a relevant role in governing gender differences in the immune
response ruling the susceptibility to autoimmune disorders. In this
context, emerging data suggest also a protective role of T through its
action on mast cells in EAE by favoring the production of IL-33, a cy-
tokine that promotes a Th2 protective response (Brown and Weinberg,
2018). Accordingly, immunized SJL females, prone to develop ag-
gressive EAE, exhibit reduced IL-33 compared to more protected male
mice (Brown and Weinberg, 2018); prevention of the disease in females
is obtained upon IL-33 administration prior to immunization (Russi
et al., 2018).
Androgens also reduce reactive microglia and astroglia after stab
wound injury (Barreto et al., 2007; Garcia-Estrada et al., 1993), de-
myelination by cuprizone (Hussain et al., 2013), neurotoxic insults by
1-methyl-4-phenylpyridinium (MPP+) (Tomas-Camardiel et al., 2002)
and suppress pro-inflammatory cytokines expression induced by Aβ in
vitro and in vivo (Yao et al., 2017).
Experimental approaches used to test androgens anti-inflammatory
activity are usually performed in females or gonadectomized males,
suggesting that androgens potential therapeutic effect might be un-
veiled when depleted.
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10.2. Neuroimmune control by estrogens, progesterone and progesterone
metabolites.
Differently from T, which generally depresses immune response,
estradiol shows immunostimulatory responses at physiological levels to
became immunosuppressive at supraphysiological levels (Kovacs et al.,
2002). Concerning the CNS, this dual activity seems also to be depen-
dent on regional and astrocyte-type differences (Larson, 2018).
Estrogens and progestins exert as well an anti-inflammatory action
in different pathological contests ranging from autoimmune to neuro-
degenerative diseases and TBI (Arevalo et al., 2012b). Four main fea-
tures are affected: morphological glial activation and proliferation,
cytokine production and release, differentiation of myeloid cells and
lymphocytes and migration of immune cells.
Both exogenous and endogenous PROG reduce the number of acti-
vated microglia and astrocytes, as measured based on ionized calcium-
binding adapter molecule 1 (Iba1) and glial fibrillary acidic protein
(GFAP) expression, after middle cerebral artery occlusion (Dang et al.,
2011; Wali et al., 2016; Zhu et al., 2017), spinal cord transection
(Labombarda et al., 2011) and demyelination (Garay et al., 2009). Si-
milar effects are reproduced by 17β-E (Barreto et al., 2007; Dang et al.,
2011; Sribnick et al., 2005; Vegeto et al., 2001; Viviani et al., 2002).
Accordingly, reduced glia activation is reflected in a decreased pro-
duction of inflammatory factors such as pro-inflammatory cytokines,
chemokines and nitric oxide, as observed upon lipopolysaccharide
(LPS) exposure of astrocytes or microglia in the presence of PROG or
17β-E (Cerciat et al., 2010; Dodel et al., 1999; Drew and Chavis, 2000;
Kipp et al., 2007; Vegeto et al., 2001). This effect relies on decreasing
nuclear factor kB (NFkB) nuclear translocation both for PROG or 17β-E
(Dodel et al., 1999; Ghisletti et al., 2005; Lei et al., 2014; Vegeto et al.,
2001) that is extended also to macrophages, monocytes and neutrophils
(Kramer et al., 2004; Miller et al., 2004; Murphy et al., 2010). In ad-
dition, 17β-E inhibition of NFkB induced by IL-1β in endothelial cells
correlates with the decreased expression of adhesion molecules like
intercellular adhesion molecule 1 (ICAM1), opposing to penetration of
circulating cells in the CNS due to the role in transmigration of leuko-
cytes across the BBB. 17β-E reduction of the chemokine receptor C-X-C
Motif Chemokine Receptor 2 (CXCR2) in monocyte and neutrophils also
contributes to limit circulating cells chemotaxis after cytokine stimu-
lation or injury (Geraldes et al., 2006; Lei et al., 2003; Miller et al.,
2004).
Finally, estrogenic anti-inflammatory action and recovery of the
damaged tissue is prompted by 17β-E promotion of Treg cells
(Palaszynski et al., 2004a) and estriol increased expression of anti-in-
flammatory cytokines (IL-10 and TGF-β) at expenses of pro-in-
flammatory ones (IL-12 and IL-6) (Douin-Echinard et al., 2008). It is
important also to highlight that metabolites of PROG and DHT also
affect neuroinflammation (Giatti et al., 2012). For instance, in EAE
model, THP treatment reduces immunoreactivity for Iba1, a mono-
cytoid cell marker, and for CD3ε, a lymphocytic marker, in the lumbar
spinal cord (Noorbakhsh et al., 2011). In this experimental model, the
metabolite of T, DHT, is also able to reduce gliosis (Giatti et al., 2015b).
In TBI experimental model, THP decreases the expression of IL-1β and
TNF-α (He et al., 2004) and increases the expression of a potent
Fig. 5. The CNS immune system: anatomical structures and cell types involved in the neuroinflammatory response. A variety of cell types at different locations
participate in the CNS immune response: microglia, astrocytes and resident mast cells in the parenchyma; macrophages, T/B cells, neutrophils, dendritic cells (DCs),
granulocytes and resident mast cells in the choroid plexus; CD4+ lymphocytes, antigen presenting cells and monocytes in the cerebrospinal fluid (CSF) and
macrophages, monocytes, mast cells, neutrophils, DCs and granulocytes in the meninges.
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inhibitor of the complement convertases that are activators of the in-
flammatory cascade, such as CD55 (VanLandingham et al., 2007).
It is important to bear in mind that neuroinflammation is physio-
logically needed to counteract infection and favors maintenance and
recovery of the nervous tissue upon abnormal challenges, such as toxins
exposure or endogenous protein deposition. In addition, activation of
specific immune cells, like microglia, is required in specific develop-
mental windows to shape neuronal circuits. Indeed, a successful im-
mune response has to be tightly regulated to avoid an excessive or an
undue response, possibly leading to the damage of the surrounding
tissue. The switch from a pro-inflammatory to an anti-inflammatory
phenotype operated by sex hormones is undoubtedly an advantage.
This mode of action, in fact, not only turns off the aggressive phase of
neuroinflammation but also promotes the recovering phase.
10.3. Sex-dependent features of immune cells that might impact on
dimorphic inflammatory response in the adult brain
Immune surveillance relies on specific features of the cells involved
that allow to organize the best response, i.e. expression of pathogen- or
damage-associated molecular patterns (PAMPs and DAMPs), changes in
cell number and changes in morphology. Sex differences of these fea-
tures are part of the brain sexual differentiation and, although their
functional role is so far unclear, might represent a molecular basis to
understand the different incidence of neurological diseases in males and
females (Hanamsagar and Bilbo, 2016).
Sex differences in number, morphology and gene expression start
since the early postnatal stages and evolve along development, con-
tributing to sex-specific organization of the brain and behavior (Fig. 6)
(Nelson et al., 2019). In the adult brain, a higher number of astrocytes
has been observed in male than female hippocampus, medial amygdala
and suprachiasmatic nucleus (Acaz-Fonseca et al., 2016) and astrocytes
display a more complex morphology in male than female medial
amygdala and arcuate nucleus of the hypothalamus (Acaz-Fonseca
et al., 2016). In contrast, in the early adulthood (P60, rat) females have
more microglia with thick and long processes than males in the hip-
pocampus, amygdala and parietal cortex (Schwarz et al., 2012).
The pattern of expression of cytokines, chemokines and their re-
ceptors is also different in female and male adult brain. Thus, IL-10 and
its receptor antagonist, IL-6, IL-1α, cluster of differentiation molecule
11b (CD-11b) and Toll-interacting protein (TOLLIP) gene expression is
increased in females, while males display higher IL-18, CC motif
Chemokine Receptor 4 (CCR4) and CC motif ligand 22 (CCL22) gene
expression (Schwarz et al., 2012). A recent study (Villa et al., 2018)
indicates a higher expression of genes associated to inflammatory
processes, including regulation of cell migration and cytokine produc-
tion, in male than female microglia isolated from the whole adult brain.
Although the functional significance of most of these differences re-
mains to be investigated, this last study provides indication that female
microglia is better adapted than male microglia to limit ischemic da-
mage independently from the hormonal environment (Villa et al.,
2018).
In addition to astrocytes and microglia, resident macrophages have
higher Toll Like Receptors (TLRs) expression and phagocytic activity in
females than males (Scotland et al., 2011). Since TLRs are components
of the innate immune system that respond to infectious ligand and
endogenous molecule released upon brain tissue producing in-
flammatory cytokines, it has been hypothesized that this sex-dependent
Fig. 6. Sex differences in immuno-competent cell types. Sex differences in cell number, cell morphology and/or in the molecular and cellular responses of microglia,
astrocytes and resident macrophages have been detected in different models of neuroinflammation.
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feature might contribute to a greater response in females.
As discussed in this section, neuroinflammation is a common treat
characterizing several different pathologies, thus identifying the mole-
cular basis ruling sex differences might represent a unique challenge to
develop a sex-targeted therapy based on neuroactive steroids.
11. Conclusions and perspectives
As here reviewed, the capability of the nervous system to synthesize
and metabolize neuroactive steroids is a well-ascertained concept.
Furthermore, recent studies have shown that the levels of neuroactive
steroids in the nervous system show sex differences that do not ne-
cessarily reflect similar sex differences in plasma levels, suggesting a
specific effect on neurosteroidogenesis. This is particularly evident
under pathological conditions in which not only the levels of neu-
roactive steroids but also the expression of steroidogenic molecules and
enzymes are differentially affected in the nervous system of males and
females. Given its neuroprotective actions, the sex-dimorphic mod-
ifications in the levels of neuroactive steroids in the nervous system
under pathological conditions may contribute to further generate sex
differences in the manifestation of the pathological alterations.
However, it remains to be determined in which conditions sex differ-
ences in neuroactive steroid levels are causal agents in the generation of
the sex differences in neurodegenerative and psychiatric disorders or
when are a consequence of such sex differences in pathology. Indeed,
the literature on these aspects is still poor and most of the data have
been obtained in only one sex. In particular, further research is needed
to determine the implications of sex differences in neurosteroidogenesis
for brain healthy aging and the diseases of the nervous system asso-
ciated with aging.
Systematic analyses of sex differences in the neuroactive steroid
field are important to determine the possibility for sex-specific diag-
nostics and therapy based on these molecules. Further studies should
also characterize functional targets of neuroactive steroids, such as the
regulation of neuroinflammation, that may contribute to identify sex-
specific therapeutic interventions. In addition, to avoid possible side
effects of the systemic treatment with neuroactive steroids or their
synthetic ligands, future therapeutic strategies may be oriented to
target specifically in each sex the neurosteroidogenesis by molecules
modulating cholesterol availability, cholesterol transport or the activity
of key steroidogenic enzymes.
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